Kraig Biocraft Laboratories Recaps Year of Breakthrough Achievements with BAM-1 Hybrids
Kraig Biocraft Laboratories (OTCQB: KBLB) reports significant achievements in 2024 with its BAM-1 hybrids, the world's first commercially viable silkworms for recombinant spider silk production. The breakthrough technology has demonstrated remarkable results, including doubled cocoon size compared to traditional silkworms and enhanced silk yields. The company produced over 1,200 pounds of recombinant spider silk cocoons this year.
The BAM-1 hybrids' exceptional robustness and resilience have advanced scalability and consistency for large-scale commercial operations. Applications include technical textiles, defense, medical devices, and performance apparel. The company plans to expand production to multiple tons of spider silk in 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) riporta risultati significativi nel 2024 con i suoi ibridi BAM-1, i primi bachi da seta commercialmente viabili al mondo per la produzione di seta di ragno ricombinante. La tecnologia innovativa ha mostrato risultati straordinari, incluso il raddoppio della dimensione dei bozzoli rispetto ai tradizionali bachi da seta e un aumento della produzione di seta. Quest'anno, l'azienda ha prodotto oltre 1.200 libbre di bozzoli di seta di ragno ricombinante.
La straordinaria robustezza e resilienza degli ibridi BAM-1 hanno migliorato la scalabilità e la coerenza delle operazioni commerciali su larga scala. Le applicazioni comprendono tessuti tecnici, difesa, dispositivi medici e abbigliamento performante. L'azienda prevede di espandere la produzione a diverse tonnellate di seta di ragno nel 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) informa sobre logros significativos en 2024 con sus híbridos BAM-1, los primeros gusanos de seda comercialmente viables en el mundo para la producción de seda de araña recombinante. La tecnología innovadora ha demostrado resultados notables, incluyendo el tamaño de capullo duplicado en comparación con los gusanos de seda tradicionales y un mayor rendimiento de seda. La compañía produjo más de 1.200 libras de capullos de seda de araña recombinante este año.
La excepcional robustez y resiliencia de los híbridos BAM-1 han avanzado la escalabilidad y consistencia para operaciones comerciales en gran escala. Las aplicaciones incluyen textiles técnicos, defensa, dispositivos médicos y ropa de alto rendimiento. La compañía planea expandir la producción a múltiples toneladas de seda de araña en 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 2024년에 재조합 거미실크 생산을 위한 세계 최초의 상업적으로 실행 가능한 누에인 BAM-1 하이브리드로 중요한 성과를 보고합니다. 이 혁신적인 기술은 전통적인 누에에 비해 두 배 큰 누에 고치 크기와 향상된 실크 생산량을 포함하여 놀라운 결과를 보여주었습니다. 회사는 올해 1,200파운드의 재조합 거미실크 고치를 생산했습니다.
BAM-1 하이브리드의 뛰어난 강인성과 회복력은 대규모 상업 운영을 위한 확장성과 일관성을 개선했습니다. 응용 분야에는 기술 섬유, 방어, 의료 기기, 성능 의류 등이 포함됩니다. 회사는 2025년까지 거미실크의 생산을 여러 톤으로 확대할 계획입니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) fait état de réalisations significatives en 2024 avec ses hybrides BAM-1, les premières vers à soie commerciaux viables au monde pour la production de soie d'araignée recombinante. Cette technologie innovante a montré des résultats remarquables, notamment la taille des cocons doublée par rapport aux vers à soie traditionnels et un rendement en soie accru. L'entreprise a produit plus de 1.200 livres de cocons de soie d'araignée recombinante cette année.
La robustesse et la résilience exceptionnelles des hybrides BAM-1 ont amélioré la scalabilité et la cohérence des opérations commerciales à grande échelle. Les applications incluent les textiles techniques, la défense, les dispositifs médicaux et les vêtements de performance. L'entreprise prévoit d'élargir sa production à plusieurs tonnes de soie d'araignée en 2025.
Kraig Biocraft Laboratories (OTCQB: KBLB) berichtet über signifikante Erfolge im Jahr 2024 mit seinen BAM-1-Hybriden, den weltweit ersten kommerziell tragfähigen Seidenraupen zur Produktion von rekombinanter Spinnenseide. Die bahnbrechende Technologie hat bemerkenswerte Ergebnisse gezeigt, darunter verdoppelte Kokongrößen im Vergleich zu traditionellen Seidenraupen und verbesserte Seiden-erträge. Das Unternehmen produzierte in diesem Jahr über 1.200 Pfund rekombinante Spinnenseidenkokons.
Die außergewöhnliche Robustheit und Resilienz der BAM-1-Hybriden haben die Skalierbarkeit und Konsistenz für groß angelegte kommerzielle Operationen vorangetrieben. Anwendungen sind technische Textilien, Verteidigung, medizinische Geräte und Leistungskleidung. Das Unternehmen plant, die Produktion bis 2025 auf mehrere Tonnen Spinnenseide auszudehnen.
- Doubled cocoon size compared to traditional silkworms
- Produced over 1,200 pounds of recombinant spider silk cocoons in 2024
- Plans for scaling to multiple tons of production in 2025
- Enhanced silkworm robustness and resilience improving commercial viability
- None.
World's First Commercially Viable Silkworms for Recombinant Spider Silk Production
ANN ARBOR, Mich., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of spider silk-based fibers, reflects on a year of extraordinary progress following the introduction of its groundbreaking BAM-1 hybrids—the world's first commercially viable silkworms recombinant spider silk production.
Since their debut earlier this year, the BAM-1 hybrids have proven to be a transformative innovation, driving significant advancements in silk production, cocoon size, yield, and silkworm robustness. These achievements validate the Company’s pioneering technology and its potential to revolutionize biomaterial manufacturing.
Over the past year, the BAM-1 hybrids have delivered remarkable results, including a doubling of cocoon size compared to traditional silkworms. This dramatic increase has directly translated to significantly higher silk yields, establishing new performance standards for productivity and efficiency in spider silk production.
In addition to improved yields, BAM-1 hybrids have demonstrated exceptional robustness and resilience. Their enhanced performance has been instrumental in advancing the scalability and consistency required for large-scale commercial operations, resulting in more than 1,200 pounds of recombinant spider silk cocoon production this year.
The BAM-1 hybrids are the world's first silkworm for commercially viable recombinant spider silk production. By achieving reliable and repeatable yields at scale, Kraig Labs has set a new industry benchmark and opened the door to a wide range of applications, including technical textiles, defense, medical devices, and performance apparel.
"The introduction of the BAM-1 hybrid earlier this year marked a turning point for Kraig Biocraft Laboratories and for the future of spider silk production," said Kim Thompson, CEO and Founder of Kraig Labs. "The extraordinary gains in cocoon size, silk yield, and silkworm resilience have validated our technology and enabled us to take significant steps toward industrial-scale production. This year has been about transforming promise into progress, and we are proud of what we have accomplished with BAM-1. Next year, we will expand on this success with production planning underway for multiple tons of spider silk production in 2025."
The Company’s ongoing innovations and achievements in 2024 position Kraig Labs as a global leader in sustainable, high-performance spider silk production, unlocking new possibilities in biomaterials.
For more details about this breakthrough and other advancements the Company has made this year, please see the Company's investor conference at www.kraiglabs.com/videos or through the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e0a1956b-f241-4864-9b08-fc0e09a2d1d2
FAQ
What production volume did KBLB achieve with BAM-1 hybrids in 2024?
How much larger are KBLB's BAM-1 hybrid cocoons compared to traditional silkworms?
What is KBLB's production target for spider silk in 2025?
What are the main applications for KBLB's spider silk technology?
What makes KBLB's BAM-1 hybrids commercially viable?
